{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":12,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":12,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"59bc5d409406","filters":{"venue":"PharmaDeals Review"}},"results":[{"id":"W150401912","doi":"10.3833/pdr.v2011i6.1485","title":"Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Milestone; Type 2 diabetes; Payment; Obesity; Quarter (Canadian coin); Business; Diabetes mellitus; Internal medicine; Finance; Endocrinology; Geography","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08240199183654418,"gpt":0.3650932836274937,"spread":0.2826912917909495,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001581792,0.001540021,0.0009635446,0.001429958,0.0004931893,0.001082871,0.000734316,0.001917712,0.1334855],"category_scores_gemma":[0.002202543,0.0006473921,0.0007753851,0.0009025202,0.0006898682,0.001209942,0.0008683789,0.002272449,0.06861438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005524302,"about_ca_system_score_gemma":0.002675557,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004254906,"about_ca_topic_score_gemma":0.006558937,"domain_scores_codex":[0.9992042,0.0001092574,0.00004960927,0.0001372257,0.0004027111,0.00009706282],"domain_scores_gemma":[0.9991739,0.0002290674,0.0000900053,0.00006821009,0.0002447188,0.0001939372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001295465,0.0002989865,0.0004804939,0.003519294,0.0001056793,0.001309269,0.0001783223,0.0002522063,0.07511213,0.01126578,0.2641882,0.6419942],"study_design_scores_gemma":[0.0006006438,0.0006570631,0.001560555,0.0005742679,0.00009260792,0.001508994,0.0000463114,0.0002577152,0.007291645,0.001214279,0.9861712,0.00002478072],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.01510758,0.2437104,0.01829716,0.01572483,0.006165507,0.002422601,0.00841501,0.004159301,0.6859975],"genre_scores_gemma":[0.04371347,0.07704128,0.01714911,0.002613166,0.0007278643,0.001062857,0.006328654,0.0003896276,0.850974],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.1334855,"threshold_uncertainty_score":0.4465535,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W131397720","doi":"10.3833/pdr.v2011i5.1473","title":"Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Business","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2517164448078097,"gpt":0.4365977792055006,"spread":0.1848813343976909,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001654032,0.0004662272,0.0003862891,0.0007936595,0.0008306077,0.001328372,0.0003869409,0.002161229,0.09689659],"category_scores_gemma":[0.001942438,0.0002218568,0.0004956229,0.0005744928,0.0006051756,0.001461825,0.0008080305,0.001384685,0.02050132],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001255632,"about_ca_system_score_gemma":0.00375134,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004392122,"about_ca_topic_score_gemma":0.007614599,"domain_scores_codex":[0.9988667,0.0001440941,0.00006069465,0.0001411869,0.000646494,0.0001408869],"domain_scores_gemma":[0.9985608,0.0003518925,0.0001801835,0.00008863005,0.0004819341,0.0003364381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007164581,0.0002657504,0.001039307,0.00108507,0.00002843492,0.001425951,0.0003197742,0.0001117426,0.03154284,0.02873776,0.2962039,0.6385229],"study_design_scores_gemma":[0.00006243974,0.0002047092,0.001162147,0.0001638501,0.00001084073,0.000837556,0.00004455167,0.00004723129,0.003163948,0.0004229859,0.9938725,0.000007235813],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.009744058,0.07652071,0.001979284,0.01843196,0.002474131,0.0002979362,0.0008507904,0.0003910136,0.8893101],"genre_scores_gemma":[0.09663953,0.0444077,0.005419466,0.007118955,0.001763259,0.0002258042,0.001679595,0.0001813293,0.8425643],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.09689659,"threshold_uncertainty_score":0.3241514,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W73664796","doi":"10.3833/pdr.v2013i11.1991","title":"Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Revenue; Stock (firearms); Business; Corporate tax; Offset (computer science); Irish; Footprint; Order (exchange); Emerging markets; Finance; Geography; Engineering; Tax avoidance; Double taxation; Mechanical engineering","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2162782767136228,"gpt":0.427603316892974,"spread":0.2113250401793512,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001280362,0.0002641557,0.0002570437,0.001047712,0.0002984819,0.001454579,0.0003242605,0.0009513542,0.01963042],"category_scores_gemma":[0.002578112,0.00008386374,0.0005301933,0.001268773,0.0003240334,0.001059998,0.0004197325,0.001072143,0.002242462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001837633,"about_ca_system_score_gemma":0.002093106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02723389,"about_ca_topic_score_gemma":0.05106479,"domain_scores_codex":[0.9996245,0.00009017874,0.00001884507,0.00004916399,0.0001658628,0.00005138755],"domain_scores_gemma":[0.9987024,0.0004716112,0.0001398681,0.00004421292,0.0005277016,0.0001142184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006755798,0.0002187108,0.007109669,0.002053077,0.0001934316,0.0003609727,0.0002130202,0.0005393877,0.001981186,0.06048524,0.2908146,0.6353551],"study_design_scores_gemma":[0.0001438764,0.0003587939,0.01403551,0.0008236641,0.0001334849,0.0003019602,0.0002850734,0.00009200839,0.0005907546,0.002614325,0.9806002,0.00002033107],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.0464006,0.3579051,0.002483157,0.1267775,0.002904572,0.0002022125,0.002334969,0.0002428074,0.4607491],"genre_scores_gemma":[0.3387353,0.3793762,0.006573167,0.05770441,0.002635677,0.0001916113,0.002746976,0.0001256411,0.2119111],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.02723389,"threshold_uncertainty_score":0.06567025,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W49293275","doi":"10.3833/pdr.v2012i2.1678","title":"Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Anesthesia and Neurotoxicity Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Xenon; General partnership; Medicine; Medical physics; Business; Engineering ethics; Medical education; Engineering; Physics; Finance; Nuclear physics","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1851774888707091,"gpt":0.4072948621059432,"spread":0.2221173732352341,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002901367,0.0009676749,0.0005072088,0.001589233,0.0008175701,0.002484447,0.001007604,0.00351283,0.0837457],"category_scores_gemma":[0.003460975,0.0002749193,0.0007403853,0.001308138,0.0008498791,0.002564354,0.001418373,0.002813766,0.02293837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004434014,"about_ca_system_score_gemma":0.01167314,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02622554,"about_ca_topic_score_gemma":0.04267529,"domain_scores_codex":[0.9972791,0.0002689219,0.00008192947,0.0002850748,0.001697357,0.0003876914],"domain_scores_gemma":[0.9972695,0.0003978957,0.0001843063,0.0001299245,0.00109447,0.0009239982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004563009,0.0002712413,0.0009097789,0.0009225262,0.00005324159,0.0007946364,0.0002317479,0.0002454347,0.01361656,0.03634191,0.4800492,0.4661074],"study_design_scores_gemma":[0.00008304426,0.0001338141,0.0005637835,0.000120316,0.00001961637,0.0007275178,0.00005860523,0.0001043086,0.002362813,0.0009724523,0.9948421,0.00001165763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.007459962,0.3106348,0.01318826,0.06642397,0.0102671,0.0009565212,0.001516421,0.001654067,0.5878989],"genre_scores_gemma":[0.04115101,0.09075748,0.0157759,0.01442453,0.001474906,0.0003066673,0.002073193,0.0003191107,0.8337173],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.0837457,"threshold_uncertainty_score":0.2801572,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2309079920","doi":"10.3833/pdr.v2014i9.2063","title":"Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis","year":2014,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Pirfenidone; Medicine; Franchise; Idiopathic pulmonary fibrosis; Asthma; Omalizumab; Internal medicine; Business; Business administration; Lung; Immunology","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02739605113640022,"gpt":0.3444773393026677,"spread":0.3170812881662675,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001015939,0.0009920998,0.0005878015,0.001086823,0.0003627275,0.001287275,0.000653081,0.003093891,0.09892388],"category_scores_gemma":[0.001251573,0.0002486524,0.0007315212,0.000598411,0.0003588129,0.001247579,0.0006108484,0.002263648,0.06751117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006685389,"about_ca_system_score_gemma":0.001103321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001796392,"about_ca_topic_score_gemma":0.003650979,"domain_scores_codex":[0.9995159,0.00006643868,0.0000212415,0.00007296883,0.0002555687,0.00006790166],"domain_scores_gemma":[0.9994124,0.0001164242,0.00006609215,0.00002517649,0.0001715095,0.0002082624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003984029,0.0002292098,0.0002051537,0.001265297,0.00004160004,0.0006435866,0.00003338397,0.0001020607,0.005754207,0.005687973,0.4382179,0.5474213],"study_design_scores_gemma":[0.0001679779,0.0002253866,0.0003587424,0.000287976,0.00001290173,0.0008997417,0.00001033664,0.00003024764,0.0006897605,0.0004275905,0.9968818,0.000007470554],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.00223454,0.6296595,0.00198528,0.02636408,0.00960632,0.0004130268,0.0008859815,0.0007009719,0.3281502],"genre_scores_gemma":[0.0311942,0.347559,0.005582581,0.02692126,0.00584899,0.0003674513,0.00186087,0.000210605,0.5804551],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.09892388,"threshold_uncertainty_score":0.3309334,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W205713971","doi":"10.3833/pdr.v2012i1.1646","title":"Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Diverse Perspectives in Modern Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Divestment; Prestige; Business; Cash; Shareholder; Database transaction; Order (exchange); Hard core; Advertising; Commerce; Finance; Corporate governance","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09439475362979195,"gpt":0.3269323725384922,"spread":0.2325376189087002,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00182797,0.000246748,0.0005426061,0.0008051156,0.001025337,0.001999249,0.0005236886,0.002675051,0.05602863],"category_scores_gemma":[0.005455383,0.0001627471,0.0003428881,0.001205201,0.0005723414,0.001363936,0.0005073645,0.001388065,0.01067045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002120287,"about_ca_system_score_gemma":0.005974111,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02267655,"about_ca_topic_score_gemma":0.05566669,"domain_scores_codex":[0.9984648,0.0001202342,0.00007888328,0.0001670553,0.0009962813,0.0001726955],"domain_scores_gemma":[0.9962584,0.001220096,0.000285878,0.0001716298,0.001712308,0.0003517182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00023599,0.0000766377,0.00284962,0.0009241605,0.00006278174,0.0006690553,0.0002412376,0.0000967841,0.001481791,0.05755085,0.7329201,0.202891],"study_design_scores_gemma":[0.00003517952,0.00007712884,0.003707801,0.0002520218,0.00003145422,0.0003595573,0.0001894322,0.00005828841,0.0003834987,0.00149805,0.9933962,0.00001133982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.01979373,0.08040004,0.001410526,0.1056875,0.002682778,0.0002030512,0.001469855,0.0002842186,0.7880682],"genre_scores_gemma":[0.156352,0.05970527,0.002650691,0.0690725,0.002511574,0.0001806347,0.002051172,0.0001367378,0.7073393],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.05602863,"threshold_uncertainty_score":0.1874344,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W202721108","doi":"10.3833/pdr.v2011i8.1518","title":"Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"China; Latin Americans; Medicine; International trade; Political science; Business; Law","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2007572896715127,"gpt":0.3865174937509864,"spread":0.1857602040794737,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002662905,0.0003889595,0.0004597503,0.001063964,0.0003500095,0.001457281,0.0008252811,0.001703191,0.1439676],"category_scores_gemma":[0.005050316,0.0001778913,0.0005700029,0.001171913,0.0005825903,0.001309672,0.0008994285,0.00172355,0.04015435],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007978524,"about_ca_system_score_gemma":0.003182795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002576058,"about_ca_topic_score_gemma":0.002662391,"domain_scores_codex":[0.9989219,0.0002744734,0.00008405196,0.0001330793,0.0004341297,0.0001524167],"domain_scores_gemma":[0.9966663,0.0007982728,0.0007506192,0.0003941259,0.0007706656,0.0006200696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000777273,0.0002231812,0.0007613942,0.0009033764,0.00005372454,0.0002506187,0.0000822887,0.0002035207,0.006517567,0.03715644,0.5498837,0.4031871],"study_design_scores_gemma":[0.0002739336,0.0002531122,0.001667369,0.0002187574,0.00002096598,0.0004410708,0.0000191541,0.0001972942,0.001360234,0.00148319,0.9940578,0.000007103149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.01219346,0.09399467,0.006678995,0.0379365,0.003047443,0.0006643456,0.008750983,0.002432851,0.8343008],"genre_scores_gemma":[0.1474195,0.04921106,0.006931272,0.01273683,0.002522433,0.0004706221,0.01227568,0.0004918466,0.7679408],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.1439676,"threshold_uncertainty_score":0.4816196,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2314904138","doi":"10.3833/pdr.v2011i9.1548","title":"PerkinElmer Agrees to Acquire Caliper Life Sciences for US$600 M","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Calipers; Portfolio; Cash; Business; Database transaction; Quarter (Canadian coin); Marketing; Computer science; Finance; Engineering; Mechanical engineering","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3463556383388496,"gpt":0.4810681235141742,"spread":0.1347124851753246,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006475443,0.002259838,0.002271617,0.003814646,0.001100055,0.002649818,0.002396838,0.003448825,0.1429391],"category_scores_gemma":[0.00682002,0.001258379,0.001016842,0.001994582,0.001290183,0.003344132,0.001232135,0.0031944,0.1868971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001276951,"about_ca_system_score_gemma":0.002838579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001592992,"about_ca_topic_score_gemma":0.003856615,"domain_scores_codex":[0.9947228,0.0006571985,0.0002499941,0.0006923196,0.003444294,0.0002333523],"domain_scores_gemma":[0.99458,0.001135453,0.0004365453,0.0004791388,0.002757202,0.0006117196],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004795287,0.0001700673,0.0004174458,0.001535158,0.00005935725,0.0003062893,0.0001206223,0.0002477099,0.08294902,0.01029811,0.4628399,0.4405768],"study_design_scores_gemma":[0.00005213527,0.0002560123,0.0007409189,0.0001012733,0.00004336256,0.001002481,0.00004535378,0.0005207333,0.01990024,0.001395128,0.9759074,0.00003502912],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.01037413,0.1832777,0.1507443,0.03940703,0.01460623,0.002597205,0.0087952,0.01781172,0.5723864],"genre_scores_gemma":[0.02590879,0.05970994,0.1008628,0.006882512,0.002666968,0.001081536,0.01318779,0.002133946,0.7875657],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.1429391,"threshold_uncertainty_score":0.4781789,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W128615782","doi":"10.3833/pdr.v2012i3.1692","title":"Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Dupuytren's Contracture and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Political science; Medicine; Management; Family medicine; Economics","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06126565779868655,"gpt":0.3962955412368063,"spread":0.3350298834381197,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002621183,0.0005304883,0.0005332141,0.001037676,0.00199472,0.001880594,0.0006451095,0.003560573,0.09390334],"category_scores_gemma":[0.003369813,0.0002199333,0.0004972218,0.0009458678,0.0008291047,0.001512825,0.001106458,0.002052225,0.01200351],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005287513,"about_ca_system_score_gemma":0.01831947,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1662775,"about_ca_topic_score_gemma":0.2388276,"domain_scores_codex":[0.9985885,0.0001378027,0.0000542331,0.0001758532,0.0007862832,0.0002572338],"domain_scores_gemma":[0.9977776,0.0003724053,0.0001847341,0.0001053212,0.0009298237,0.0006301191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004341755,0.0001358349,0.001048402,0.0008429805,0.00003544075,0.001348931,0.0004143852,0.0001797467,0.0057224,0.07652231,0.511485,0.4018304],"study_design_scores_gemma":[0.00002597018,0.00004619831,0.0006132753,0.0001384762,0.000007858091,0.0003028322,0.00003317638,0.00002956588,0.0003133956,0.0002203023,0.9982645,0.000004534212],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.005963983,0.105775,0.00141675,0.05407439,0.003588605,0.0003424591,0.0009113024,0.0003539542,0.8275736],"genre_scores_gemma":[0.04293984,0.04030872,0.001879217,0.01283222,0.001218984,0.000170094,0.0006602557,0.00007757852,0.8999131],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.8337225,"threshold_uncertainty_score":0.3306194,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2285884689","doi":"10.3833/pdr.v2012i11.1832","title":"Pfizer Forays into ADHD Market by Exercising Option to Acquire NextWave Pharmaceuticals","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Quarter (Canadian coin); Business; Medicine; Psychiatry","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1161500219915705,"gpt":0.458131856071382,"spread":0.3419818340798115,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007301227,0.0009631045,0.0005006178,0.001426583,0.0005389513,0.001504138,0.0005006803,0.002432239,0.354789],"category_scores_gemma":[0.00199358,0.0002844558,0.0005879113,0.0005849539,0.0004134785,0.001770592,0.0007962301,0.002207016,0.1376358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006443365,"about_ca_system_score_gemma":0.001825024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001986972,"about_ca_topic_score_gemma":0.004608601,"domain_scores_codex":[0.9995481,0.00002766904,0.00001592375,0.00007479545,0.0002813334,0.00005207978],"domain_scores_gemma":[0.9991074,0.0001114945,0.00009435968,0.00004198205,0.0002764528,0.0003682996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002500426,0.0001808693,0.0002628044,0.0002303896,0.0000145724,0.0002881914,0.00002335868,0.00004959593,0.002564241,0.003964542,0.6998959,0.2922755],"study_design_scores_gemma":[0.0002243819,0.0002571747,0.0007173675,0.0001508493,0.00001853122,0.0005001185,0.00001872234,0.00009966559,0.0007765574,0.000685299,0.996542,0.000009175999],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.003909172,0.05146358,0.003399841,0.04139585,0.008696157,0.0007575919,0.004173867,0.002913131,0.8832909],"genre_scores_gemma":[0.01945558,0.02571335,0.00465543,0.009294651,0.003993914,0.0002271772,0.003469971,0.00033594,0.9328539],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.354789,"threshold_uncertainty_score":0.9203153,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W9436761","doi":"10.3833/pdr.v2011i9.1531","title":"Sanofi’s Aventis Pharma Subsidiary to Acquire Nutraceuticals Business of India’s Universal Medicare","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Business; Nutraceutical; Portfolio; Quarter (Canadian coin); Marketing; Finance; Medicine","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1334269315679914,"gpt":0.3308779048758859,"spread":0.1974509733078945,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002047176,0.0003082514,0.0003245865,0.001235271,0.0004179163,0.001974131,0.0003802266,0.001617025,0.03140919],"category_scores_gemma":[0.004791903,0.0001619315,0.0004349726,0.001156094,0.0003454881,0.0007828615,0.0003375796,0.001573107,0.008136394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002562708,"about_ca_system_score_gemma":0.01029806,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01124549,"about_ca_topic_score_gemma":0.01388079,"domain_scores_codex":[0.9988564,0.0001780475,0.00006208833,0.00010296,0.0006169943,0.0001834527],"domain_scores_gemma":[0.9952103,0.001293205,0.0004946711,0.0001612573,0.002237542,0.0006029101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002259671,0.00007135675,0.00165169,0.0006989079,0.00005602395,0.0001520821,0.00003986789,0.0002618,0.000729394,0.0571146,0.8242633,0.114735],"study_design_scores_gemma":[0.00009742545,0.0001013137,0.005466511,0.0003090166,0.00003581116,0.0001710056,0.00003946508,0.0001832174,0.0004735681,0.001398828,0.9917133,0.00001047741],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.0120241,0.2030298,0.002240098,0.2330635,0.006268869,0.0004485614,0.005481721,0.0004257718,0.5370175],"genre_scores_gemma":[0.1700444,0.1920935,0.00396483,0.05396205,0.004721317,0.0003533787,0.005461279,0.0001137682,0.5692855],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.03140919,"threshold_uncertainty_score":0.1050742,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1578951455","doi":"10.3833/pdr.v2013i4.1921","title":"Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Alliance; Product (mathematics); Disease; Political science; Business; Medicine; Internal medicine","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1399369246955383,"gpt":0.4159867448974022,"spread":0.276049820201864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00275203,0.0009159296,0.0006559682,0.001254327,0.0007452261,0.002097477,0.0009494157,0.003727893,0.07126162],"category_scores_gemma":[0.002336863,0.0002700367,0.0007636113,0.0006457422,0.0005622657,0.001813126,0.001483549,0.003398668,0.03158728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001876775,"about_ca_system_score_gemma":0.007500759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002843133,"about_ca_topic_score_gemma":0.00612886,"domain_scores_codex":[0.9988396,0.0001665495,0.00006041754,0.0001744224,0.0004752715,0.000283869],"domain_scores_gemma":[0.9977841,0.0002575922,0.0001774662,0.00008140405,0.0007004321,0.0009990651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002444213,0.0008646699,0.001062841,0.001345896,0.0000775047,0.001202894,0.0001629679,0.0001541089,0.005585977,0.01321016,0.5802145,0.3936743],"study_design_scores_gemma":[0.0006043005,0.0005216733,0.001307179,0.0002848134,0.00004438988,0.0005823004,0.00004928002,0.00006250526,0.001164658,0.000800557,0.9945683,0.000009970758],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.02473153,0.2999873,0.00467266,0.1104214,0.02309155,0.002393031,0.008060788,0.001744661,0.5248971],"genre_scores_gemma":[0.06760731,0.09946405,0.007400306,0.01901569,0.003370883,0.001078976,0.008507386,0.0003441818,0.7932113],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.07126162,"threshold_uncertainty_score":0.2383938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}